Lupin Chemicals  Ltd (LCL) was promoted by Lupin Laboratories Ltd. The
 company was incorporated on 31.03.83 as a Private Ltd company and
 subsequently converted into a Public Ltd company with effect from
 23.12.91. The company does not have any subsidary.
 
 The company is setting up a project for the manufacture of 93 tpa of
 Rifampicin, an essential anti-tuberculosis, anti-leprotic, life
 saving drug from a very basic stage of fermentation. It is an import
 substitute product. To finance the project the company is  coming out
 with a PCD issue aggregating to Rs.45.6 crores.
 
 2002
 -Lupin Ltd has successfully introduced AkuriT, a revolutionary
 simplified therapy as per 
 WHO's guidelines for treatment of tuberculosis
 
 -Crisil has upgraded the rating assigned to Lupin's non-convertible
 debentures from 
 D to BB+.
 
 -Lupin Ltd has enhanced its capacity of manufacturing various
 products at its formulations
 plants at Aurangabad and Manideep in Madhya Pradesh.
 
 2007
 
 - Lupin receives Final FDA Approval for Trandolapril.
 
 -Lupin Ltd inducted PricewaterHouseCoopers  to implement SAP to
 faultlessly connect
 its 28 sales depot.
 
 -Lupin Ltd has cut down its debt by Rs.20cr .
 
 2003
 
 -Lupin Ltd has commissioned its facility at Mandideep near Bhopal,
 Madhya Pradesh 
 for the manufacture of Lisinopril.
 
 -Lupin Ltd announces VRS  for its employees in a bid to trim its wage
 bill.
 
 -Pharmaceutical major Lupin Ltd has divested about 12.55% of its
 equity holding in
 the company to CVC International, a private investment arm of the US
 based 
 financial conglomerate Citigroup.
 
 -Lupin is closing down its South African Operations and is setting up
 two subsidiaries
 in Hongkong and the US.
 
 -Lupin Ltd has received the appproval of US Food and Drug
 Administration for
 cefuroxime axetil 250 mg and 500 mg tablets.
 
 Dr.Kamal K Sharma has been appointed as the Additional Director of
 the company.
 
 -The company has received USFDA's approval for cefotaxime sterile
 vials for injection. 
 
 -Secured US FDA nod for generic Claforan marketing
 
 -Lupin receives USFDA approval for Caftriaxone Sterile Vials for
 injections
 
 -Lupin plans to list shares on NYSE
 
 -Lupin set up new herbal product division
 
 -Lupin submits INDA for psoriasis
 
 2004
 
 -Launches Ezedoc, a specialty drug for the cholesterol management
 segment
 
 -Lupin has appointed Vinod Dhawan as President - Business Development
 (Latin America, Japan, Australia, and New Zealand). Mr.Dhawan will be
 responsible for the development of Lupin's business strategy for
 these markets, with focus on, among others, product selection, entry
 strategy, marketing and sales, and regulatory compliance.
 
 -Lupin Limited has informed that at the EGM of the Company held on
 December 05, 2003, the members of the Company have by means of a
 special resolution determined to delist shares of the Company, from
 the following exchanges : 1) The Calcutta Stock Exchange Association
 Ltd. 2) The Stock Exchange, Ahmedabad, 3) Jaipur Stock Exchange Ltd.,
 4) The Delhi Stock Exchange Association Ltd. The Company has initiated
 action to secure de-listing of the equity shares of the Company, from
 the aforesaid exchanges. The Equity shares of the Company are listed
 on the NSE and BSE and will continue to be listed and traded on NSE
 and BSE.
 
 -Enters into an agreement with Baxter Healthcare Corporation, a
 global medical products company headquartered in the United States,
 whereby Baxter will exclusively distribute the Company's generic
 version of ceftriaxone sterile vials for injection in the USA
 
 - Floats new division - Lupin Herbal, dedicated to research-based
 phytomedicines. Unveiled nine herbal products in therapeutic areas,
 including diabetes, pediatrics, gastro intestinal, pain management
 and gynaecology
 
 2004
 
 -Delists Shares from Ahmedabad Stock Exchange.
 
 - Lupin Pharmaceuticals, Inc., wholly owned subsidiary of the Company
 has entered into an agreement with Allergan, Inc. in the United States
 to promote Zymar (gatifloxacin opthalmic solution) 0.3% in the
 pediatric specialty area.
 
 -Lupin Ltd  has launched its anti-infective product Suprax (cefixime
 Oral Suspension) in the US market.
 
 -Shares of Lupin Ltd delisted from the Delhi Stock Exchange
 
 - Shares of Lupin Ltd delisted from Jaipur Stock Exchange
 
 -  Ind Swift Ltd ties up with Lupin Ltd for a Co-marketing pact to
 launch Nitazoxanide, an anti-diarrhoeal / anti-helmintic drug for the
 first time in India under the brand name Netazox and Nizonide
 respectively.
 
 2005
 
 -Lupin launches Ceftriaxone vials in the US market
 
 -Lupin enters into co-operation agreement with Kyowa for Japanese
 market.
 
 -Lupin receives USFDA approvals for Cephalexin Oral Suspension
 
 -Lupin has entered into an agreement with GSK Philippines to
 manufacture and supply the 4 & 2 Drug FDCs for marketing in
 Philippines.
 
 -Lupin receives approval for conducting phase II clinical trials of
 Investigation New Drug candidate LLL-3348 (Desoris) from the Drug
 Controller General of India.
 
 2006
 
 -Lupin joins hands with ItalFarmaco to launch Lupenox in India
 
 -Lupin receives DCGI approval to conduct Phase II clinical Trials for
 Psoriasis NCE
 
 -Lupin & Aspen Pharmacare enters into MoU for establishment of JV
 
 -Lupin joins hands with ItalFarmaco to launch Lupenox in India
 
 -Lupin Ltd has announced that the Company has signed a MoU to acquire
 a 51% equity in Artifex Finance CVA, Belgium, along with its
 subsidiaries including Dafra Pharma Ltd (Dafra), a Belgian
 pharmaceutical Company focussed on anti-malaria
 
 -Lupin ties up with Italian co
 
 2007
 
 - Lupin Receives US FDA Approval for Simvastatin Tablets
 
 - Lupin gets MHRA Approval for Lisinopril in UK
 
 - Lupin Ltd has announced that it has received Euro 20 million from
 Laboratoires Servier of France for the sale of additional patent
 rights for Perindopril.
 
 -Lupin receives DCGI Approval to conduct Combined Phase IIb/III
 Clinical Trials for it's herbal Psoriasis NCE
 
 -Lupin Ltd on April 27, 2007, has announced that theDepartment of
 Science and Technology (DST), Government of India and the Company
 have joined hands for the clinical development of the Company's
 Migraine and Psoriasis projects.
 
 -Lupin receives Best New Manufacturer of the Year Award from
 AmerisourceBergen
 
 2008
 
 -Lupin Limited has appointed Mr. R.V. Satam as Secretary & Compliance
 Officer of the Company w.e.f. May 01, 2008.
 
 -Lupin enters into agreement for Suprax 400 mg tablets
 
 -Lupin Launches SUPRAX ®400 mg Tablets in the US
 
 -Lupin expands its product basket in JapanKyowa receives Ten product
 approvals
 
 2009
 
 -Lupin receives USFDA approval for Levetiracetam Tablets
 
 -Lupin ties up with leading Institutes for PhD Program
 
 -Lupin in Equity Partnership with Multicare Pharmaceuticals
 Philippines, Inc.
 
 -Lupin Expands Branded Play; Announces Acquisition of Worldwide
 Rights for its first NDA - AllerNaze
 
 2010
 
 -  Lupin Limited has launched Ilyalgan® (sodium hyaluronate), an
 osteoarthritis drug, available in the form of an injectable through
 leading orthopaedics and physiotherapists across the country.
 Hyalgan40 is the original research molecule of the Italian pharma
 giant I-'IDIA and is the world leader in HA therapy, marketed in over
 60 countries globally.
 
 - Lupin Limited's U.S subsidiary, Lupin Pharmaceuticalss Inc. (LPT)
 has received the final approval for the company's Abbreviated New
 Drug Application (ANDA) for its Imipramine Pamoate capsules, 75 mg,
 100 mg, 125 mg and 150 mg from the U.S. Food and Drug Administration
 (FDA). Commercial shipments of the product have already commenced.